Literature DB >> 15764680

Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply.

Malgorzata Tokarska-Schlattner1, Michael Zaugg, Rafaela da Silva, Eliana Lucchinetti, Marcus C Schaub, Theo Wallimann, Uwe Schlattner.   

Abstract

Doxorubicin (DXR) is a widely used and efficient anticancer drug. However, its application is limited by the risk of severe cardiotoxicity. Impairment of cardiac high-energy phosphate homeostasis is an important manifestation of both acute and chronic DXR cardiotoxic action. Using the Langendorff model of the perfused rat heart, we characterized the acute effects of 1-h perfusion with 2 or 20 microM DXR on two key kinases in cardiac energy metabolism, creatine kinase (CK) and AMP-activated protein kinase (AMPK), and related them to functional responses of the perfused heart and structural integrity of the contractile apparatus as well as drug accumulation in cardiomyocytes. DXR-induced changes in CK were dependent on the isoenzyme, with a shift in protein levels of cytosolic isoenzymes from muscle-type CK to brain-type CK, and a destabilization of octamers of the mitochondrial isoenzyme (sarcometric mitochondrial CK) accompanied by drug accumulation in mitochondria. Interestingly, DXR rapidly reduced the protein level and phosphorylation of AMPK as well as phosphorylation of its target, acetyl-CoA-carboxylase. AMPK was strongly affected already at 2 microM DXR, even before substantial cardiac dysfunction occurred. Impairment of CK isoenzymes was mostly moderate but became significant at 20 microM DXR. Only at 2 microM DXR did upregulation of brain-type CK compensate for inactivation of other isoenzymes. These results suggest that an impairment of kinase systems regulating cellular energy homeostasis is involved in the development of DXR cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15764680     DOI: 10.1152/ajpheart.01057.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  34 in total

1.  Inhibition of AMP-activated protein kinase pathway sensitizes human leukemia K562 cells to nontoxic concentration of doxorubicin.

Authors:  Qun Zhu; Bo Shen; Boshao Zhang; Wei Zhang; Steve H Chin; Junfei Jin; Duan-fang Liao
Journal:  Mol Cell Biochem       Date:  2010-03-26       Impact factor: 3.396

Review 2.  Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms.

Authors:  Jessica M Scott; Aarif Khakoo; John R Mackey; Mark J Haykowsky; Pamela S Douglas; Lee W Jones
Journal:  Circulation       Date:  2011-08-02       Impact factor: 29.690

3.  Inhibition of AMP-activated protein kinase α (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1.

Authors:  Shaobin Wang; Ping Song; Ming-Hui Zou
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 4.  The creatine kinase system and pleiotropic effects of creatine.

Authors:  Theo Wallimann; Malgorzata Tokarska-Schlattner; Uwe Schlattner
Journal:  Amino Acids       Date:  2011-03-30       Impact factor: 3.520

Review 5.  AMP-activated protein kinase, stress responses and cardiovascular diseases.

Authors:  Shaobin Wang; Ping Song; Ming-Hui Zou
Journal:  Clin Sci (Lond)       Date:  2012-06       Impact factor: 6.124

6.  Davallialactone protects against adriamycin-induced cardiotoxicity in vitro and in vivo.

Authors:  Sankarganesh Arunachalam; Sun Young Kim; Sun Hwa Lee; Young Hee Lee; Min Sun Kim; Bong Sik Yun; Ho Keun Yi; Pyoung Han Hwang
Journal:  J Nat Med       Date:  2011-08-21       Impact factor: 2.343

Review 7.  Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

Authors:  Michel G Khouri; Pamela S Douglas; John R Mackey; Miguel Martin; Jessica M Scott; Marielle Scherrer-Crosbie; Lee W Jones
Journal:  Circulation       Date:  2012-12-04       Impact factor: 29.690

8.  Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity.

Authors:  Yunfang Zhang; Haitham El-Sikhry; Ketul R Chaudhary; Sri Nagarjun Batchu; Anooshirvan Shayeganpour; Taibeh Orujy Jukar; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Page Myers; Douglas C Rouse; Julie Foley; Abraham Nyska; Darryl C Zeldin; John M Seubert
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

9.  The role of cell death and myofibrillar damage in contractile dysfunction of long-term cultured adult cardiomyocytes exposed to doxorubicin.

Authors:  Francesco Timolati; Tobias Anliker; Vittoria Groppalli; Jean-Claude Perriard; Hans M Eppenberger; Thomas M Suter; Christian Zuppinger
Journal:  Cytotechnology       Date:  2009-11-05       Impact factor: 2.058

Review 10.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.